Status:
NOT_YET_RECRUITING
Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort
Lead Sponsor:
Independent Medical Alliance
Collaborating Sponsors:
Open Source Medicine Foundation OU
Conditions:
Vaccine Adverse Reaction
Post Acute Covid-19 Vaccination Syndrome
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to evaluate whether metabolic modulation with a combined nutraceutical product can improve symptoms and metabolic health in adults diagnosed with post-acute Covid-19...
Eligibility Criteria
Inclusion
- Persistent fatigue lasting more than 6 months
- Received at least one dose of a Covid-19 vaccine, after which they experienced fatigue symptoms (symptom onset within two weeks of vaccination)
- Laboratory result showing persistent spike protein in blood OR presence of spike protein antibodies with SARS-CoV-2 nucleocapsid antibodies negative.
Exclusion
- Pregnant
- History of Schizophrenia
- Currently using antidepressant medication
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06967428
Start Date
September 1 2025
End Date
January 1 2026
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dorrington Medical Associates
Houston, Texas, United States, 77030